Model-informed drug development (MIDD) can increase confidence in yours.
For more than three decades, we’ve partnered with scientists and teams across the drug lifecycle—supporting ADMET prediction, PBPK, pharmacometrics, and QSP/QST with trusted software and expert guidance.
And now, you can leverage our mechanistic models and AI-enabled workflows in an integrated environment, moving you from discovery to submission with confidence.
GastroPlus is a mechanistically based simulation software package that simulates intravenous, oral, oral cavity, ocular, inhalation, dermal, subcutaneous, and intramuscular absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals.
ADMET Predictor is the flagship machine learning platform for ADMET modeling with extended capabilities for data analysis, metabolism prediction, and AI-driven drug design.
DILIsym is Quantitative Systems Toxicology (QST) software designed to be used during drug development to provide an indication of the potential drug-induced liver injury (DILI) hazard posed by individual molecules and/or to provide deeper insight into the mechanisms responsible for observed DILI responses at various stages of the development process.
Thales is end-to-end quantitative systems pharmacology (QSP) platform for building models, optimizing simulated populations to clinical data, and visualizing and analyzing simulation results.
The Pro-ficiency Performance Management platform is a next generation learning engine that houses complex content and any other content you need for training. Unlike your LMS, with our solution you get lifelike simulation, detailed data tracking, and beautiful analytics.
Our experienced scientists are ready to help you at any stage of the drug development lifecycle, from discovery through commercialization.
Learn more about what we offer.
